In support of this, the EGFR inhibitor AG1478 and siRNA for EGFR were used in our study and the data showed that up-regulation of MMP-2 expression and phosphorylation of ERK1/2 were reversed by the treatments in RCC cells. This evidence concerns the gene MAPK3 and renal cell carcinoma.